Paxlovid components, molecular models. The image shows the two components of paxlovid, PF-07321332 (bottom) and ritonavir (top). PF-07321332 is a new antiviral drug acting as a protease inhibitor in the treatment of COVID-19. Ritonavir slows down the metabolism of PF-07321332. As of 2021, paxlovid is in phase III trials. | |
Licence : | Droits gérés |
Crédit: | Science Photo Library / Laguna Design |
Taille de l’image : | 4150 px × 4150 px |
Model Release : | Non requis |
Property Release : | Non requis |
Restrictions : | - |